TWI388349B - 眼用裝置及相關方法及組合物 - Google Patents
眼用裝置及相關方法及組合物 Download PDFInfo
- Publication number
- TWI388349B TWI388349B TW094127770A TW94127770A TWI388349B TW I388349 B TWI388349 B TW I388349B TW 094127770 A TW094127770 A TW 094127770A TW 94127770 A TW94127770 A TW 94127770A TW I388349 B TWI388349 B TW I388349B
- Authority
- TW
- Taiwan
- Prior art keywords
- collagen
- composition
- corneal
- inlay
- edc
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 98
- 238000000034 method Methods 0.000 title claims description 26
- 102000008186 Collagen Human genes 0.000 claims description 251
- 108010035532 Collagen Proteins 0.000 claims description 251
- 229920001436 collagen Polymers 0.000 claims description 251
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 118
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 41
- 230000010261 cell growth Effects 0.000 claims description 34
- 229920000642 polymer Polymers 0.000 claims description 34
- 238000004132 cross linking Methods 0.000 claims description 21
- 230000002378 acidificating effect Effects 0.000 claims description 20
- 210000005036 nerve Anatomy 0.000 claims description 17
- 239000007952 growth promoter Substances 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 230000012010 growth Effects 0.000 claims description 15
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 12
- 239000003431 cross linking reagent Substances 0.000 claims description 12
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 10
- 241001465754 Metazoa Species 0.000 claims description 10
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 10
- 229920002674 hyaluronan Polymers 0.000 claims description 10
- 229960003160 hyaluronic acid Drugs 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 9
- 102000012422 Collagen Type I Human genes 0.000 claims description 8
- 108010022452 Collagen Type I Proteins 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 7
- MWOGMBZGFFZBMK-LJZWMIMPSA-N (2s)-2-[[(2s)-2-[[2-[[(2s,3s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 MWOGMBZGFFZBMK-LJZWMIMPSA-N 0.000 claims description 4
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims description 4
- 102000015336 Nerve Growth Factor Human genes 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 229940053128 nerve growth factor Drugs 0.000 claims description 4
- 108010052768 tyrosyl-isoleucyl-glycyl-seryl-arginine Proteins 0.000 claims description 4
- XQQUSYWGKLRJRA-RABCQHRBSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s,3s)-2-amino-3-methylpentanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-3-methylbutanoic acid Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O XQQUSYWGKLRJRA-RABCQHRBSA-N 0.000 claims description 3
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 claims description 3
- 102000007072 Nerve Growth Factors Human genes 0.000 claims description 3
- 150000001413 amino acids Chemical group 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- 108010088381 isoleucyl-lysyl-valyl-alanyl-valine Proteins 0.000 claims description 3
- 239000003900 neurotrophic factor Substances 0.000 claims description 3
- 229920001504 poly(N-isopropylacrylamide-co-acrylic acid) Polymers 0.000 claims description 3
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 230000001851 biosynthetic effect Effects 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 229940116977 epidermal growth factor Drugs 0.000 claims description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 2
- 241001474374 Blennius Species 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000000017 hydrogel Substances 0.000 description 50
- 210000004087 cornea Anatomy 0.000 description 49
- 239000000463 material Substances 0.000 description 46
- 239000000499 gel Substances 0.000 description 35
- 230000003287 optical effect Effects 0.000 description 31
- 239000000243 solution Substances 0.000 description 29
- 239000007943 implant Substances 0.000 description 24
- 239000007987 MES buffer Substances 0.000 description 19
- 210000002919 epithelial cell Anatomy 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 18
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 16
- 210000004045 bowman membrane Anatomy 0.000 description 15
- 239000002953 phosphate buffered saline Substances 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 15
- 210000000981 epithelium Anatomy 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 12
- 239000011159 matrix material Substances 0.000 description 12
- 210000003560 epithelium corneal Anatomy 0.000 description 11
- 208000014733 refractive error Diseases 0.000 description 11
- 238000004925 denaturation Methods 0.000 description 10
- 230000036425 denaturation Effects 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 238000012937 correction Methods 0.000 description 9
- 230000004438 eyesight Effects 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 102000001187 Collagen Type III Human genes 0.000 description 7
- 108010069502 Collagen Type III Proteins 0.000 description 7
- 230000004075 alteration Effects 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 238000002513 implantation Methods 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 238000002834 transmittance Methods 0.000 description 7
- 241000283690 Bos taurus Species 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 230000003628 erosive effect Effects 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 230000000007 visual effect Effects 0.000 description 6
- 230000005540 biological transmission Effects 0.000 description 5
- 229920001222 biopolymer Polymers 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 208000010247 contact dermatitis Diseases 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000000386 microscopy Methods 0.000 description 5
- 210000002241 neurite Anatomy 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 238000006116 polymerization reaction Methods 0.000 description 5
- -1 polypropylene Polymers 0.000 description 5
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 238000000149 argon plasma sintering Methods 0.000 description 4
- 201000009310 astigmatism Diseases 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000012456 homogeneous solution Substances 0.000 description 4
- 238000003364 immunohistochemistry Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 231100000065 noncytotoxic Toxicity 0.000 description 4
- 230000002020 noncytotoxic effect Effects 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 3
- 229920002101 Chitin Polymers 0.000 description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
- 206010020675 Hypermetropia Diseases 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 229940072056 alginate Drugs 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 210000000871 endothelium corneal Anatomy 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000036571 hydration Effects 0.000 description 3
- 238000006703 hydration reaction Methods 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 208000001491 myopia Diseases 0.000 description 3
- 230000004379 myopia Effects 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 210000001525 retina Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 229920001410 Microfiber Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 229920006355 Tefzel Polymers 0.000 description 2
- 210000002159 anterior chamber Anatomy 0.000 description 2
- 239000000607 artificial tear Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940096422 collagen type i Drugs 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 210000003683 corneal stroma Anatomy 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- QHSJIZLJUFMIFP-UHFFFAOYSA-N ethene;1,1,2,2-tetrafluoroethene Chemical compound C=C.FC(F)=C(F)F QHSJIZLJUFMIFP-UHFFFAOYSA-N 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 201000006318 hyperopia Diseases 0.000 description 2
- 230000004305 hyperopia Effects 0.000 description 2
- 150000002466 imines Chemical class 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000009434 installation Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000003658 microfiber Substances 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- 239000007793 ph indicator Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 201000010041 presbyopia Diseases 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 238000010526 radical polymerization reaction Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000003594 spinal ganglia Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- PZBPKYOVPCNPJY-UHFFFAOYSA-N 1-[2-(allyloxy)-2-(2,4-dichlorophenyl)ethyl]imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=C)CN1C=NC=C1 PZBPKYOVPCNPJY-UHFFFAOYSA-N 0.000 description 1
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- JKYKXTRKURYNGW-UHFFFAOYSA-N 3,4-dihydroxy-9,10-dioxo-9,10-dihydroanthracene-2-sulfonic acid Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C(O)=C(O)C(S(O)(=O)=O)=C2 JKYKXTRKURYNGW-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 102000004510 Collagen Type VII Human genes 0.000 description 1
- 108010017377 Collagen Type VII Proteins 0.000 description 1
- 206010011013 Corneal erosion Diseases 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102400001369 Heparin-binding EGF-like growth factor Human genes 0.000 description 1
- 101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102000000426 Integrin alpha6 Human genes 0.000 description 1
- 108010041100 Integrin alpha6 Proteins 0.000 description 1
- 229920000288 Keratan sulfate Polymers 0.000 description 1
- 102000005373 Keratin-3 Human genes 0.000 description 1
- 108010070918 Keratin-3 Proteins 0.000 description 1
- 208000010415 Low Vision Diseases 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-N alpha-L-IdopA-(1->3)-beta-D-GalpNAc4S Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS(O)(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C(O)=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000000571 coke Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000004453 corneal transparency Effects 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 210000002555 descemet membrane Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 208000011323 eye infectious disease Diseases 0.000 description 1
- 230000004424 eye movement Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000001724 microfibril Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000013425 morphometry Methods 0.000 description 1
- NALMPLUMOWIVJC-UHFFFAOYSA-N n,n,4-trimethylbenzeneamine oxide Chemical compound CC1=CC=C([N+](C)(C)[O-])C=C1 NALMPLUMOWIVJC-UHFFFAOYSA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000001682 neurofibril Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000005015 neuronal process Effects 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000004493 normal intraocular pressure Effects 0.000 description 1
- 238000007248 oxidative elimination reaction Methods 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000036417 physical growth Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000011697 sodium iodate Substances 0.000 description 1
- 229940032753 sodium iodate Drugs 0.000 description 1
- 235000015281 sodium iodate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 230000003746 surface roughness Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 239000012780 transparent material Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000009790 vascular invasion Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/24—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/14—Eye parts, e.g. lenses or corneal implants; Artificial eyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
- A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- G—PHYSICS
- G02—OPTICS
- G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
- G02B1/00—Optical elements characterised by the material of which they are made; Optical coatings for optical elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/16—Materials or treatment for tissue regeneration for reconstruction of eye parts, e.g. intraocular lens, cornea
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Biophysics (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Dispersion Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60127004P | 2004-08-13 | 2004-08-13 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW200618824A TW200618824A (en) | 2006-06-16 |
| TWI388349B true TWI388349B (zh) | 2013-03-11 |
Family
ID=35839107
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW094127770A TWI388349B (zh) | 2004-08-13 | 2005-08-15 | 眼用裝置及相關方法及組合物 |
| TW094127763A TWI288630B (en) | 2004-08-13 | 2005-08-15 | Vision enhancing ophthalmic devices and related methods and compositions |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW094127763A TWI288630B (en) | 2004-08-13 | 2005-08-15 | Vision enhancing ophthalmic devices and related methods and compositions |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20060134170A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP1776148B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2008508959A (cg-RX-API-DMAC7.html) |
| KR (2) | KR101298442B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN101018513B (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0514349A (cg-RX-API-DMAC7.html) |
| CA (2) | CA2576308C (cg-RX-API-DMAC7.html) |
| TW (2) | TWI388349B (cg-RX-API-DMAC7.html) |
| WO (2) | WO2006015490A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8668735B2 (en) | 2000-09-12 | 2014-03-11 | Revision Optics, Inc. | Corneal implant storage and delivery devices |
| KR20050042819A (ko) * | 2002-09-13 | 2005-05-10 | 오큘라 사이언시즈, 인크. | 시력 개선 장치 및 방법 |
| US8185209B2 (en) * | 2003-01-03 | 2012-05-22 | Board Of Trustees Operating Michigan State University | Methods to extend vision to infrared wavelengths |
| US10835371B2 (en) | 2004-04-30 | 2020-11-17 | Rvo 2.0, Inc. | Small diameter corneal inlay methods |
| KR20070055422A (ko) | 2004-05-20 | 2007-05-30 | 쿠퍼비젼,인코포레이티드 | 시력 향상을 위한 각막 온레이 및 파면 수차 보정 |
| BRPI0514349A (pt) * | 2004-08-13 | 2008-06-10 | Ottawa Health Research Inst | dispositivos oftálmicos para o reforço da visão e métodos e composições relacionadas |
| US8029515B2 (en) * | 2005-01-31 | 2011-10-04 | Yichieh Shiuey | Corneal implants and methods and systems for placement |
| US7261412B2 (en) * | 2005-06-30 | 2007-08-28 | Visx, Incorporated | Presbyopia correction through negative high-order spherical aberration |
| CN101305052B (zh) * | 2005-09-09 | 2012-10-10 | 渥太华健康研究所 | 互穿网络和相关方法及组合物 |
| US10555805B2 (en) | 2006-02-24 | 2020-02-11 | Rvo 2.0, Inc. | Anterior corneal shapes and methods of providing the shapes |
| US7883520B2 (en) | 2006-04-10 | 2011-02-08 | Forsight Labs, Llc | Corneal epithelial pocket formation systems, components and methods |
| EP2019646A4 (en) * | 2006-05-04 | 2013-12-04 | Herbert Kaufman | METHOD, DEVICE AND SYSTEM FOR THE RELEASE OF A THERAPEUTIC ACTIVE IN THE EYE |
| WO2008013557A1 (en) * | 2006-07-24 | 2008-01-31 | International Stem Cell Corporation | Synthetic cornea from retinal stem cells |
| US7959284B2 (en) | 2006-07-25 | 2011-06-14 | Lai Shui T | Method of making high precision optics having a wavefront profile |
| WO2008014419A2 (en) | 2006-07-26 | 2008-01-31 | Lai Shui T | Intrastromal surgery correcting low order and high order aberrations of the eye |
| ES2668641T3 (es) * | 2006-07-26 | 2018-05-21 | Shui T. Lai | Cirugía intraestromal para corregir aberraciones de bajo orden y de alto orden del ojo |
| US20110212524A1 (en) * | 2006-12-04 | 2011-09-01 | Body Organ Biomedical Corporation | Biomaterial and preparation method thereof |
| US7746649B2 (en) * | 2007-01-08 | 2010-06-29 | Rockwell Automation Technologies, Inc. | Modular soft starter |
| US9549848B2 (en) | 2007-03-28 | 2017-01-24 | Revision Optics, Inc. | Corneal implant inserters and methods of use |
| US9271828B2 (en) | 2007-03-28 | 2016-03-01 | Revision Optics, Inc. | Corneal implant retaining devices and methods of use |
| CA2687990A1 (en) * | 2007-05-23 | 2008-12-04 | Allergan, Inc. | Cross-linked collagen and uses thereof |
| US20080300679A1 (en) * | 2007-06-01 | 2008-12-04 | Altmann Griffith E | Diffractive Intraocular Lens |
| EP2221334B1 (en) * | 2007-11-28 | 2016-12-28 | FUJIFILM Corporation | Method for chemically modifying biopolymer and polypeptide |
| WO2009084507A1 (ja) * | 2007-12-28 | 2009-07-09 | Osaka University | 積層コラーゲンゲルの作製方法及び積層コラーゲンゲル |
| JP5586579B2 (ja) | 2008-04-04 | 2014-09-10 | ネクシスビジョン， インコーポレイテッド | 疼痛管理および視力のための治療装置 |
| US9539143B2 (en) | 2008-04-04 | 2017-01-10 | Revision Optics, Inc. | Methods of correcting vision |
| CA2720573C (en) | 2008-04-04 | 2019-08-13 | Revision Optics, Inc. | Corneal inlay design and methods of correcting vision |
| AU2009246520B2 (en) | 2008-05-12 | 2012-04-19 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
| US9095404B2 (en) | 2008-05-12 | 2015-08-04 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
| US9877973B2 (en) | 2008-05-12 | 2018-01-30 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
| US10064819B2 (en) | 2008-05-12 | 2018-09-04 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
| JP5388090B2 (ja) * | 2008-05-29 | 2014-01-15 | 国立大学法人東北大学 | 強膜透明化による角膜移植材料調製方法 |
| US8198248B2 (en) * | 2008-08-15 | 2012-06-12 | Orthopeutics, Lp | Formulations for nonsurgical exogenous crosslink therapy |
| US8283322B2 (en) * | 2008-08-15 | 2012-10-09 | Orthopeutics, Lp | Formulations for nonsurgical exogenous crosslink therapy |
| US20100040593A1 (en) * | 2008-08-15 | 2010-02-18 | Orthopeutics, Lp | Formulations for nonsurgical exogenous crosslink therapy |
| JP5722217B2 (ja) | 2008-09-02 | 2015-05-20 | アラーガン・ホールディングス・フランス・ソシエテ・パール・アクシオン・サンプリフィエＡｌｌｅｒｇａｎ Ｈｏｌｄｉｎｇｓ Ｆｒａｎｃｅ Ｓ．Ａ．Ｓ． | ヒアルロン酸および／またはその誘導体の糸、その作製方法、ならびにその使用 |
| US20100198348A1 (en) * | 2009-01-30 | 2010-08-05 | Hiles Michael C | Biomaterials with modified optical character and methods for preparing and using same |
| JP5988588B2 (ja) * | 2009-03-10 | 2016-09-07 | ザ ジョーンズ ホプキンズ ユニバーシティＴｈｅ Ｊｏｈｎｓ Ｈｏｐｋｉｎｓ Ｕｎｉｖｅｒｓｉｔｙ | 生物学的組織結合及び修復装置及びその使用方法 |
| EP2483332B1 (en) * | 2009-09-30 | 2018-06-20 | Ottawa Hospital Research Institute | Crosslinked hydrogels and related method of preparation |
| WO2011050365A1 (en) | 2009-10-23 | 2011-04-28 | Forsight Labs, Llc | Conformable therapeutic shield for vision and pain |
| EP3260092A1 (en) | 2009-10-23 | 2017-12-27 | Nexisvision, Inc. | Corneal denervation for treatment of ocular pain |
| US20110172180A1 (en) | 2010-01-13 | 2011-07-14 | Allergan Industrie. Sas | Heat stable hyaluronic acid compositions for dermatological use |
| PL3078388T3 (pl) | 2010-03-22 | 2019-08-30 | Allergan, Inc. | Usieciowane hydrożele do powiększania tkanek miękkich |
| CN201689229U (zh) * | 2010-06-04 | 2010-12-29 | 柏登生医股份有限公司 | 具有角膜修补功能的隐形眼镜 |
| US9622911B2 (en) | 2010-09-30 | 2017-04-18 | Cxl Ophthalmics, Llc | Ophthalmic treatment device, system, and method of use |
| EP2644620B1 (en) * | 2010-11-26 | 2017-06-28 | Tokyo Institute of Technology | Non-fibrogenesis collagen material and a manufacturing method thereof |
| US8871016B2 (en) | 2011-08-03 | 2014-10-28 | The Johns Hopkins University | Cellulose-based hydrogels and methods of making thereof |
| US9211256B2 (en) | 2011-03-08 | 2015-12-15 | The Johns Hopkins University | Wound healing compositions comprising biocompatible cellulose hydrogel membranes and methods of use thereof |
| US9175153B2 (en) | 2011-03-08 | 2015-11-03 | The Johns Hopkins University | Cellulose hydrogel compositions and contact lenses for corneal applications |
| US12044905B2 (en) | 2011-04-28 | 2024-07-23 | Journey1 Inc | Contact lenses for refractive correction |
| US9186243B2 (en) * | 2011-05-31 | 2015-11-17 | Novartis Ag | Accommodative intraocular lens and method of implantation |
| RU2740454C2 (ru) | 2011-06-03 | 2021-01-14 | Аллерган Эндюстри, Сас | Составы кожного наполнителя, включая антиоксиданты |
| US9393263B2 (en) | 2011-06-03 | 2016-07-19 | Allergan, Inc. | Dermal filler compositions including antioxidants |
| US9408797B2 (en) | 2011-06-03 | 2016-08-09 | Allergan, Inc. | Dermal filler compositions for fine line treatment |
| US20130096081A1 (en) | 2011-06-03 | 2013-04-18 | Allergan, Inc. | Dermal filler compositions |
| US9662422B2 (en) | 2011-09-06 | 2017-05-30 | Allergan, Inc. | Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation |
| US20130244943A1 (en) | 2011-09-06 | 2013-09-19 | Allergan, Inc. | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications |
| RU2619654C2 (ru) | 2011-10-21 | 2017-05-17 | Ревижн Оптикс, Инк. | Устройства для хранения и подачи имплантатов роговицы |
| CN102552975B (zh) * | 2012-02-28 | 2013-09-11 | 青岛中皓生物工程有限公司 | 一种组织工程人角膜基质载体支架及其制备方法 |
| RU2475248C1 (ru) * | 2012-03-12 | 2013-02-20 | Государственное бюджетное учреждение "Уфимский научно-исследовательский институт глазных болезней Академии наук Республики Башкортостан" | Офтальмологическое средство-2 для кросслинкинга |
| WO2013148895A1 (en) | 2012-03-29 | 2013-10-03 | Cxl Ophthalmics, Llc | Ocular cross-linking system and method for sealing corneal wounds |
| EP2830627B1 (en) | 2012-03-29 | 2024-05-01 | Epion Therapeutics, Inc. | Ocular treatment solutions, delivery devices and delivery augmentation methods |
| US9566301B2 (en) | 2012-03-29 | 2017-02-14 | Cxl Ophthalmics, Llc | Compositions and methods for treating or preventing diseases associated with oxidative stress |
| JP6389820B2 (ja) * | 2012-09-06 | 2018-09-12 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | ヒアルロン酸／コラーゲン系真皮充填剤組成物およびそれを作製するための方法 |
| US10092393B2 (en) | 2013-03-14 | 2018-10-09 | Allotex, Inc. | Corneal implant systems and methods |
| EP3014345A2 (en) | 2013-06-26 | 2016-05-04 | Nexisvision, Inc. | Contact lenses for refractive correction |
| CN103333270B (zh) * | 2013-07-02 | 2016-05-11 | 武汉理工大学 | 胶原蛋白肽接枝海藻酸钠硫酸酯、制备方法及其用途 |
| EP3200838B1 (en) | 2014-09-30 | 2019-09-18 | Allergan Industrie, SAS | Stable hydrogel compositions including additives |
| KR101531479B1 (ko) * | 2014-11-21 | 2015-06-26 | 세원셀론텍(주) | 의료용 재료로 사용하기 위한 고농도 콜라겐 제조방법 |
| EP3256179B1 (en) | 2015-02-13 | 2019-11-20 | Allergan Industrie, SAS | Implants for sculpting, augmenting or correcting facial features such as the chin |
| AU2015385773A1 (en) | 2015-03-12 | 2017-10-05 | Revision Optics, Inc. | Methods of correcting vision |
| KR101690539B1 (ko) | 2015-07-30 | 2016-12-29 | 주식회사 아이바이오코리아 | 건성안 예방 또는 치료용 약학조성물 |
| US10449090B2 (en) | 2015-07-31 | 2019-10-22 | Allotex, Inc. | Corneal implant systems and methods |
| TWI635877B (zh) | 2015-12-18 | 2018-09-21 | 財團法人工業技術研究院 | 用於保護眼內組織的薄膜及其保護方法 |
| SE1551698A1 (en) * | 2015-12-22 | 2017-05-02 | Rafat Mehrdad | A composite collagen hydrogel material, an implantable ophthalmic device comprising such material and methods of producing the composite collagen hydrogel material and the implantable ophthalmic device |
| WO2017107638A1 (zh) * | 2015-12-25 | 2017-06-29 | 深圳艾尼尔角膜工程有限公司 | 一种角膜包装体的自动化分类收集系统及方法 |
| CN113456889B (zh) * | 2016-07-27 | 2022-06-28 | 珐博进(中国)医药技术开发有限公司 | 生物合成角膜 |
| WO2018232338A1 (en) | 2017-06-16 | 2018-12-20 | AesculaTech, Inc. | Thermoresponsive polymers and uses thereof |
| KR102015624B1 (ko) | 2017-11-15 | 2019-08-28 | 고려대학교산학협력단 | 데스메막 이동 부착막 |
| CN108277204A (zh) * | 2018-01-10 | 2018-07-13 | 山东麦德克斯生物科技有限公司 | 一种生物工程培育眼全层角膜的方法 |
| CN117064634A (zh) * | 2018-03-01 | 2023-11-17 | 巴伊兰大学 | 用于修正眼部状态的系统、方法及材料组成物 |
| KR101979286B1 (ko) * | 2018-05-17 | 2019-05-15 | 경북대학교병원 | 부분 경화된 콘택트렌즈형 양막 드레싱 및 이의 제조방법 |
| CN108498862A (zh) * | 2018-06-21 | 2018-09-07 | 常州大学 | 一种氧化石墨烯改性角膜修复材料及其制备方法 |
| DE102019213178A1 (de) * | 2019-08-30 | 2021-03-04 | Resorba Medical Gmbh | Polymerfolie und Polymertasche zur Aufnahme eines zu implantierenden medizinisch-technischen Produkts |
| US20230000617A1 (en) * | 2019-10-06 | 2023-01-05 | Precise Bio 3D Ltd | Bioengineered corneal grafts |
| WO2022272082A1 (en) * | 2021-06-24 | 2022-12-29 | Rvo 2.0, Inc, D/B/A Optics Medical | Corneal onlay medical device |
| WO2022272107A1 (en) * | 2021-06-24 | 2022-12-29 | Rvo 2.0, Inc, D/B/A Optics Medical | Corneal inlay implant |
| CN113713086A (zh) * | 2021-08-20 | 2021-11-30 | 山西锦波生物医药股份有限公司 | 一种含有重组iii型人源化胶原蛋白的组合物及其制备方法和用途 |
| CN113773380A (zh) * | 2021-09-28 | 2021-12-10 | 山东汉肽医美生物科技有限公司 | 一种重组人胶原蛋白、编码基因及其在制备可生物降解的胶原基角膜替代物上的应用 |
| CN115518206B (zh) * | 2022-10-18 | 2024-01-23 | 华中科技大学同济医学院附属协和医院 | 一种自矿化gbr膜及其制备方法 |
| CN115819802B (zh) * | 2022-12-26 | 2025-08-29 | 杭州钧兴生物科技有限公司 | 一种无色透明胶原水凝胶及其制备方法 |
| CN116173303B (zh) * | 2023-04-27 | 2023-07-04 | 北赛泓升(北京)生物科技有限公司 | 一种生物鼓膜及其制备方法和应用 |
| CN120837241A (zh) * | 2025-06-05 | 2025-10-28 | 温州医科大学附属眼视光医院 | 一种角膜层间镜片植入器械及角膜层间镜片植入系统 |
Family Cites Families (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1569707A (en) * | 1922-03-29 | 1926-01-12 | Gussie M Bunnell | Dumping truck |
| US1999286A (en) * | 1933-07-12 | 1935-04-30 | Bolt Minor T De | Brake |
| FR851651A (fr) * | 1938-09-21 | 1940-01-12 | Westinghouse Freins & Signaux | Perfectionnements à la fabrication de dispositifs à conductibilité asymétrique |
| US3361200A (en) * | 1965-03-01 | 1968-01-02 | Lawrence S. Chambers | Equipment and method for servicing submarine oil wells |
| US4078564A (en) * | 1976-02-24 | 1978-03-14 | Novo Enzyme Corporation | Intralenticular cataract surgery |
| US4223984A (en) * | 1979-04-04 | 1980-09-23 | Opticol Corporation | Collagen soft contact lens |
| US4268131A (en) * | 1979-04-11 | 1981-05-19 | Opticol Corporation | Fiber collagen contact lens |
| US4581030A (en) * | 1982-09-30 | 1986-04-08 | Massachusetts General Hospital | Collagen replacement prothesis for the cornea |
| US4563779A (en) * | 1984-01-27 | 1986-01-14 | Kelman Charles D | Corneal implant and method of making the same |
| IL74715A0 (en) * | 1984-03-27 | 1985-06-30 | Univ New Jersey Med | Biodegradable matrix and methods for producing same |
| US4600533A (en) * | 1984-12-24 | 1986-07-15 | Collagen Corporation | Collagen membranes for medical use |
| WO1987001040A1 (en) * | 1985-08-23 | 1987-02-26 | Washington Research Foundation | Polymeric intraocular lens material having improved surface properties |
| US4636210A (en) * | 1985-12-09 | 1987-01-13 | Hoffer Kenneth J | Multi-part intraocular lens and method of implanting it in an eye |
| GB2185124B (en) * | 1986-01-03 | 1989-10-25 | Choyce David P | Intra-corneal implant |
| US4981841A (en) * | 1986-04-04 | 1991-01-01 | Allergan, Inc. | Methods and materials for use in corneal wound healing |
| US4799931A (en) * | 1986-05-14 | 1989-01-24 | Lindstrom Richard L | Intracorneal lens |
| US4819617A (en) * | 1986-09-04 | 1989-04-11 | University Of Florida | Viscoelastic material for ophthalmic surgery |
| US4994081A (en) * | 1986-10-16 | 1991-02-19 | Cbs Lens | Method for locating on a cornea an artificial lens fabricated from a collagen-hydrogel for promoting epithelial cell growth |
| US5112350A (en) * | 1986-10-16 | 1992-05-12 | Cbs Lens, A California General Partnership | Method for locating on a cornea an artificial lens fabricated from a collagen-hydrogel for promoting epithelial cell growth and regeneration of the stroma |
| US5114627A (en) * | 1986-10-16 | 1992-05-19 | Cbs Lens | Method for producing a collagen hydrogel |
| US4983181A (en) * | 1986-10-16 | 1991-01-08 | Cbs Lens, | Collagen hydrogel for promoting epithelial cell growth and artificial lens using the same |
| US4898461A (en) * | 1987-06-01 | 1990-02-06 | Valdemar Portney | Multifocal ophthalmic lens |
| US4810082A (en) * | 1987-07-01 | 1989-03-07 | Abel Robert Jr | Corneal onlay lens |
| US4834748A (en) * | 1987-09-29 | 1989-05-30 | Allergan, Inc. | Method and apparatus for removing corneal tissue |
| US5192316A (en) * | 1988-02-16 | 1993-03-09 | Allergan, Inc. | Ocular device |
| US5104408A (en) * | 1988-03-02 | 1992-04-14 | Thompson Keith P | Apparatus and process for application and adjustable reprofiling of synthetic lenticules for vision correction |
| US5108428A (en) * | 1988-03-02 | 1992-04-28 | Minnesota Mining And Manufacturing Company | Corneal implants and manufacture and use thereof |
| US4923467A (en) * | 1988-03-02 | 1990-05-08 | Thompson Keith P | Apparatus and process for application and adjustable reprofiling of synthetic lenticules for vision correction |
| US5936035A (en) * | 1988-11-21 | 1999-08-10 | Cohesion Technologies, Inc. | Biocompatible adhesive compositions |
| US5565519A (en) * | 1988-11-21 | 1996-10-15 | Collagen Corporation | Clear, chemically modified collagen-synthetic polymer conjugates for ophthalmic applications |
| US5475052A (en) * | 1988-11-21 | 1995-12-12 | Collagen Corporation | Collagen-synthetic polymer matrices prepared using a multiple step reaction |
| US5614587A (en) * | 1988-11-21 | 1997-03-25 | Collagen Corporation | Collagen-based bioadhesive compositions |
| US5019097A (en) * | 1989-11-22 | 1991-05-28 | Allergan, Inc. | Corneal onlay lenses and methods for attaching same |
| US5201764A (en) * | 1990-02-28 | 1993-04-13 | Autogenesis Technologies, Inc. | Biologically compatible collagenous reaction product and articles useful as medical implants produced therefrom |
| US5196027A (en) * | 1990-05-02 | 1993-03-23 | Thompson Keith P | Apparatus and process for application and adjustable reprofiling of synthetic lenticules for vision correction |
| US5288436A (en) * | 1990-11-06 | 1994-02-22 | Colloptics, Inc. | Methods of fabricating a collagen lenticule precursor for modifying the cornea |
| US5196026A (en) * | 1991-09-16 | 1993-03-23 | Chiron Ophthalmics, Inc. | Method of implanting corneal inlay lenses smaller than the optic zone |
| WO1993014133A1 (en) * | 1992-01-15 | 1993-07-22 | Allergan, Inc. | Hydrogel compositions and structures made from same |
| US5292514A (en) * | 1992-06-24 | 1994-03-08 | Minnesota Mining And Manufacturing Company | Azlactone-functional substrates, corneal prostheses, and manufacture and use thereof |
| DE69324811T2 (de) * | 1992-08-07 | 1999-09-16 | Keravision, Inc. | Intrastromaler kornealring |
| US5405384A (en) * | 1992-09-03 | 1995-04-11 | Keravision, Inc. | Astigmatic correcting intrastromal corneal ring |
| US5300118A (en) * | 1992-09-21 | 1994-04-05 | Keravision | Adjustable devices for corneal curvature adjustment |
| US5836313A (en) * | 1993-02-08 | 1998-11-17 | Massachusetts Institute Of Technology | Methods for making composite hydrogels for corneal prostheses |
| US5487895A (en) * | 1993-08-13 | 1996-01-30 | Vitaphore Corporation | Method for forming controlled release polymeric substrate |
| TW257671B (cg-RX-API-DMAC7.html) * | 1993-11-19 | 1995-09-21 | Ciba Geigy | |
| US6197019B1 (en) * | 1994-04-25 | 2001-03-06 | Gholam A. Peyman | Universal implant blank for modifying corneal curvature and methods of modifying corneal curvature therewith |
| US5496339A (en) * | 1994-05-17 | 1996-03-05 | Koepnick; Russell G. | Universal automated keratectomy apparatus and method |
| US6221067B1 (en) * | 1995-10-20 | 2001-04-24 | Gholam A. Peyman | Corneal modification via implantation |
| US5722971A (en) * | 1995-10-20 | 1998-03-03 | Peyman; Gholam A. | Intrastromal corneal modification |
| US5964748A (en) * | 1995-10-20 | 1999-10-12 | Peyman; Gholam A. | Intrastromal corneal modification |
| US6551307B2 (en) * | 2001-03-23 | 2003-04-22 | Gholam A. Peyman | Vision correction using intrastromal pocket and flap |
| US5919185A (en) * | 1997-04-25 | 1999-07-06 | Peyman; Gholam A. | Universal implant blank for modifying corneal curvature and methods of modifying corneal curvature therewith |
| US6203538B1 (en) * | 1995-11-03 | 2001-03-20 | Gholam A. Peyman | Intrastromal corneal modification |
| JP4167728B2 (ja) * | 1996-02-07 | 2008-10-22 | ロート製薬株式会社 | 粘度を調節した眼科用組成物 |
| BR9708357A (pt) * | 1996-03-27 | 1999-08-03 | Novartis Ag | Processo para produção de um polímero poroso a partir de uma mistura |
| US5876439A (en) * | 1996-12-09 | 1999-03-02 | Micooptix, Llc | Method and appartus for adjusting corneal curvature using a fluid-filled corneal ring |
| US5733334A (en) * | 1996-12-09 | 1998-03-31 | Microoptix | Method and apparatus for adjusting corneal curvature |
| US6030634A (en) * | 1996-12-20 | 2000-02-29 | The Chinese University Of Hong Kong | Polymer gel composition and uses therefor |
| US6186148B1 (en) * | 1998-02-04 | 2001-02-13 | Kiyoshi Okada | Prevention of posterior capsular opacification |
| US6036891A (en) * | 1998-05-11 | 2000-03-14 | Pharmacia & Upjohn | Polymerizable hydrophilic ultraviolet light absorbing monomers |
| US6599305B1 (en) * | 1998-08-12 | 2003-07-29 | Vladimir Feingold | Intracorneal lens placement method and apparatus |
| US6361560B1 (en) * | 1998-12-23 | 2002-03-26 | Anamed, Inc. | Corneal implant and method of manufacture |
| WO2000056354A2 (en) * | 1999-03-22 | 2000-09-28 | Boston Innovative Optics, Inc. | Methods of using agents that act on the epithelial sheet of a human eye |
| US20020039788A1 (en) * | 2000-02-29 | 2002-04-04 | Isseroff Roslyn R. | Corneal epithelial graft composites |
| US20070031473A1 (en) * | 2005-08-05 | 2007-02-08 | Peyman Gholam A | Drug delivery system and method |
| US6689165B2 (en) * | 2000-03-31 | 2004-02-10 | Board Of Supervisors Of Louisana State University And Agricultural And Mechanical College | Surface modifications for enhanced epithelialization |
| US6717651B2 (en) * | 2000-04-12 | 2004-04-06 | Nikon Corporation | Exposure apparatus, method for manufacturing thereof and method for manufacturing microdevice |
| US6338559B1 (en) * | 2000-04-28 | 2002-01-15 | University Of Rochester | Apparatus and method for improving vision and retinal imaging |
| US6544286B1 (en) * | 2000-07-18 | 2003-04-08 | Tissue Engineering Refraction, Inc. | Pre-fabricated corneal tissue lens method of corneal overlay to correct vision |
| AR030341A1 (es) * | 2000-08-14 | 2003-08-20 | Novartis Ag | Articulos biomedicos moldeados |
| US7152975B2 (en) * | 2000-11-10 | 2006-12-26 | Cooper Vision, Inc. | Junctionless ophthalmic lenses and methods for making same |
| US6547391B2 (en) * | 2000-12-08 | 2003-04-15 | Johnson & Johnson Vision Care, Inc. | Ocular aberration correction taking into account fluctuations due to biophysical rhythms |
| RU2190841C1 (ru) * | 2001-07-04 | 2002-10-10 | Общество с ограниченной ответственностью "Научно-экспериментальное производство Микрохирургия глаза" | Биосовместимый оптически прозрачный полимерный материал |
| US7156859B2 (en) * | 2001-07-23 | 2007-01-02 | Fos Holding S.A. | Device for separating the epithelium layer from the surface of the cornea of an eye |
| US6702807B2 (en) * | 2001-09-10 | 2004-03-09 | Minu, L.L.C. | Ablatable intracorneal inlay with predetermined refractive properties |
| US6860601B2 (en) * | 2002-02-06 | 2005-03-01 | John H. Shadduck | Adaptive optic lens system and method of use |
| US7476398B1 (en) * | 2002-06-28 | 2009-01-13 | Universite Laval | Corneal implant and uses thereof |
| US6855163B2 (en) * | 2002-07-19 | 2005-02-15 | Minu, Llc | Gradual correction of corneal refractive error using multiple inlays |
| AU2003254677A1 (en) * | 2002-08-09 | 2004-02-25 | Ottawa Health Research Institute | Innervated artificial tissues and uses thereof |
| EP1530600B1 (en) * | 2002-08-09 | 2007-03-14 | Ottawa Health Research Institute | Bio-synthetic matrix and uses thereof |
| US7235195B2 (en) * | 2002-09-06 | 2007-06-26 | Novartis Ag | Method for making opthalmic devices |
| KR20050042819A (ko) * | 2002-09-13 | 2005-05-10 | 오큘라 사이언시즈, 인크. | 시력 개선 장치 및 방법 |
| US7166118B2 (en) * | 2002-11-27 | 2007-01-23 | Bausch & Lomb Incorporated | Microkeratome blade assembly |
| US7186266B2 (en) * | 2003-06-06 | 2007-03-06 | Teledioptic Lens System, Llc | Bifocal intraocular telescope for low vision correction |
| EP1651946A1 (en) * | 2003-07-30 | 2006-05-03 | Novartis AG | Reflection hologram sensor in contact lens |
| US20070016292A1 (en) * | 2003-11-14 | 2007-01-18 | Edward Perez | Epithelium treatment methods and devices for treating the epithelium |
| BRPI0416791B1 (pt) * | 2003-11-19 | 2017-04-25 | Vision Crc Ltd | "sistema ocular e dispositivo ocular". |
| NZ550964A (en) * | 2004-04-28 | 2011-05-27 | Angiodevice Internat Gmbh | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use |
| KR20070055422A (ko) * | 2004-05-20 | 2007-05-30 | 쿠퍼비젼,인코포레이티드 | 시력 향상을 위한 각막 온레이 및 파면 수차 보정 |
| BRPI0514349A (pt) * | 2004-08-13 | 2008-06-10 | Ottawa Health Research Inst | dispositivos oftálmicos para o reforço da visão e métodos e composições relacionadas |
| US20060052796A1 (en) * | 2004-09-08 | 2006-03-09 | Edward Perez | Combined epithelial delaminator and inserter |
| US20060064112A1 (en) * | 2004-09-08 | 2006-03-23 | Edward Perez | Ocular device applicator |
| US20060071356A1 (en) * | 2004-10-04 | 2006-04-06 | Kevin Beebe | Method for separating excess material from a lens mold |
| US7857849B2 (en) * | 2004-10-05 | 2010-12-28 | The Board Of Trustees Of The Leland Stanford Junior Iniversity | Artificial corneal implant |
| CA2548881A1 (en) * | 2005-05-27 | 2006-11-27 | University Of Ottawa | Neoglycopolymer-cross-linked biopolymer matrix |
| US7520608B2 (en) * | 2006-03-20 | 2009-04-21 | High Performance Optics, Inc. | Color balanced ophthalmic system with selective light inhibition |
| EP2115519A4 (en) * | 2007-02-23 | 2012-12-05 | Pixeloptics Inc | DYNAMIC OPHTHALMIC OPENING |
| JP5586579B2 (ja) * | 2008-04-04 | 2014-09-10 | ネクシスビジョン， インコーポレイテッド | 疼痛管理および視力のための治療装置 |
| US20100087920A1 (en) * | 2008-10-07 | 2010-04-08 | Forsight Labs, Llc | Corneal Onlay Lenses and Related Methods for Improving Vision of Presbyopic Patients |
-
2005
- 2005-08-12 BR BRPI0514349-7A patent/BRPI0514349A/pt not_active Application Discontinuation
- 2005-08-12 WO PCT/CA2005/001240 patent/WO2006015490A1/en not_active Ceased
- 2005-08-12 JP JP2007525138A patent/JP2008508959A/ja active Pending
- 2005-08-12 JP JP2007525825A patent/JP2008509748A/ja active Pending
- 2005-08-12 WO PCT/US2005/028723 patent/WO2006020859A2/en not_active Ceased
- 2005-08-12 EP EP05772220.9A patent/EP1776148B1/en not_active Expired - Lifetime
- 2005-08-12 US US11/203,685 patent/US20060134170A1/en not_active Abandoned
- 2005-08-12 KR KR1020077003303A patent/KR101298442B1/ko not_active Expired - Fee Related
- 2005-08-12 KR KR1020077003304A patent/KR20070053217A/ko not_active Withdrawn
- 2005-08-12 CA CA2576308A patent/CA2576308C/en not_active Expired - Lifetime
- 2005-08-12 CN CN2005800269021A patent/CN101018513B/zh not_active Expired - Fee Related
- 2005-08-12 CA CA2577025A patent/CA2577025C/en not_active Expired - Fee Related
- 2005-08-12 US US11/660,135 patent/US20080269119A1/en not_active Abandoned
- 2005-08-12 EP EP05785447A patent/EP1791499A4/en not_active Withdrawn
- 2005-08-12 CN CNA2005800350485A patent/CN101132818A/zh active Pending
- 2005-08-15 TW TW094127770A patent/TWI388349B/zh not_active IP Right Cessation
- 2005-08-15 TW TW094127763A patent/TWI288630B/zh not_active IP Right Cessation
-
2010
- 2010-11-05 JP JP2010248813A patent/JP2011020001A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006020859A2 (en) | 2006-02-23 |
| EP1776148A4 (en) | 2011-08-17 |
| CN101018513A (zh) | 2007-08-15 |
| KR20070060077A (ko) | 2007-06-12 |
| US20080269119A1 (en) | 2008-10-30 |
| CA2577025C (en) | 2014-01-28 |
| EP1776148B1 (en) | 2019-03-06 |
| US20060134170A1 (en) | 2006-06-22 |
| WO2006020859A3 (en) | 2007-01-25 |
| CN101018513B (zh) | 2011-11-16 |
| KR20070053217A (ko) | 2007-05-23 |
| BRPI0514349A (pt) | 2008-06-10 |
| EP1791499A4 (en) | 2011-08-17 |
| CA2576308C (en) | 2015-06-30 |
| CA2577025A1 (en) | 2006-02-23 |
| EP1776148A1 (en) | 2007-04-25 |
| JP2011020001A (ja) | 2011-02-03 |
| TW200618824A (en) | 2006-06-16 |
| KR101298442B1 (ko) | 2013-08-22 |
| JP2008508959A (ja) | 2008-03-27 |
| CN101132818A (zh) | 2008-02-27 |
| CA2576308A1 (en) | 2006-02-16 |
| TWI288630B (en) | 2007-10-21 |
| WO2006015490A1 (en) | 2006-02-16 |
| JP2008509748A (ja) | 2008-04-03 |
| TW200628133A (en) | 2006-08-16 |
| EP1791499A2 (en) | 2007-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI388349B (zh) | 眼用裝置及相關方法及組合物 | |
| US8236344B2 (en) | Engineered proteins, and methods of making and using | |
| EP2755598B1 (en) | Fabrication of gelatin hydrogel sheet for the transplantation of corneal endothelium | |
| US20070182920A1 (en) | Corneal Onlays and Related Methods | |
| MXPA05002669A (es) | Dispositivos y metodos para mejorar la vision. | |
| MXPA06013343A (es) | Injertos corneos y correccion de aberracion de frente de ondas para mejorar la vision. | |
| CN113926001B (zh) | 一种仿生角膜及其制备方法 | |
| WO1988002622A1 (en) | Collagen-hydrogel lens for promoting epithelial cell growth | |
| JP7787610B2 (ja) | ポリエチレングリコール化コラーゲン様タンパク質の製造方法及びその使用 | |
| RU2714943C1 (ru) | Искусственная роговица, представляющая собой мембрану гетерогенной жесткости на основе коллагена, и способ ее получения и применения | |
| CN120129542A (zh) | 一种低溶胀脱细胞角膜及其制备方法和应用 | |
| WO2024223806A1 (en) | Crosslinkable liquid composition for use in a method of treating an eye disorder | |
| CN1694658A (zh) | 用于改善视力的装置和方法 | |
| HK1113755A (en) | Ophthalmic devices and related methods and compositions | |
| CN1972667A (zh) | 工程蛋白及制备和使用方法 | |
| MX2007001630A (en) | Vision enhancing ophthalmic devices and related methods and compositions | |
| AU2024262654A1 (en) | Crosslinkable liquid composition for use in a method of treating or preventing an eye disorder |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |